1. Home
  2. ENTA vs LAB Comparison

ENTA vs LAB Comparison

Compare ENTA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.96

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo Standard BioTools Inc.

LAB

Standard BioTools Inc.

HOLD

Current Price

$0.93

Market Cap

488.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
LAB
Founded
1995
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
488.4M
IPO Year
2012
2008

Fundamental Metrics

Financial Performance
Metric
ENTA
LAB
Price
$12.96
$0.93
Analyst Decision
Strong Buy
Hold
Analyst Count
5
1
Target Price
$20.40
$1.35
AVG Volume (30 Days)
155.3K
2.4M
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
44.68
EPS
N/A
N/A
Revenue
$102,814,000.00
$101,937,000.00
Revenue This Year
$5.91
N/A
Revenue Next Year
N/A
$2.63
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$0.92
52 Week High
$17.15
$1.72

Technical Indicators

Market Signals
Indicator
ENTA
LAB
Relative Strength Index (RSI) 41.06 23.76
Support Level $12.09 N/A
Resistance Level $15.52 $1.41
Average True Range (ATR) 0.81 0.07
MACD -0.15 -0.01
Stochastic Oscillator 4.86 3.02

Price Performance

Historical Comparison
ENTA
LAB

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About LAB Standard BioTools Inc.

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Share on Social Networks: